Differential treatment regimen-related effects of HU210 on CB 1 and D 2-like receptor functionality in the rat basal ganglia

Pharmacology

Volumn 89, Issue 1-2, 2012, Pages 64-73

  Nguyen, Vu H ^a   Wang, Hongqin ^a   Verdurand, Mathieu ^a,b   Zavitsanou, Katerina ^a  

^a AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION   (Australia)

^b SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

Author keywords

Agonist stimulated 35S GTP S autoradiography; Basal ganglia; CB 1 receptors; D 2 receptors; Desensitization; HU210

Indexed keywords

CANNABINOID 1 RECEPTOR; DEXANABINOL; DOPAMINE 2 RECEPTOR; G PROTEIN COUPLED RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; AUTORADIOGRAPHY; BASAL GANGLION; BRAIN REGION; DRUG DOSE REGIMEN; DRUG EFFECT; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT DURATION;

ANIMALS; BASAL GANGLIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); MALE; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; RECEPTORS, DOPAMINE D2; SULFUR RADIOISOTOPES; TETRAHYDROCANNABINOL; TIME FACTORS;

EID: 84862808821     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000335368     Document Type: Article

References (65)

1. Herkenham M, Lynn AB, de Costa BR, Richfield EK: Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res 1991; 547: 267-274.
2. Mailleux P, Vanderhaeghen JJ: Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: An in situ hybridization study. J Neurochem 1993; 61: 1705-1712.
3. Howlett AC: Pharmacology of cannabinoid receptors. Annu Rev Pharmacol Toxicol 1995; 35: 607-634.
4. Rodriguez De Fonseca F, Gorritt MA, Bilbao A, Escuredo L, Garcia-Segura LM, Piomelli D, Navarro M: Role of the endogenous cannabinoid system as a modulator of dopamine transmission: Implications for Parkinson's disease and schizophrenia. Neurotox Res 2001; 3: 23-35.
5. Sañudo-Peña MC, Walker JM: Role of the subthalamic nucleus in cannbinoid actions in the substantia nigra of the rat. J Neurophysiol 1997; 77: 1635-1638.
6. Rodriguez de Fonseca FA, Martin-Calderon JL, Del Arco I, Gorriti MA, Navarro M: Role of the endogenous cannabinoid system in the regulation of motor activity. Neurobiol Dis 1998; 5: 483-501.
7. Szabo B, Muller T, Koch H: Effects of cannabinoids on dopamine release in the corpus striatum and the nucleus accumbens in vitro. J Neurochem 1999; 73: 1084-1089.
8. Katona I, Sperlagh B, Sik A, Kofalvi A, Vizi ES, Mackie K, Freund TF: Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 1999; 19: 4544-4558.
9. Katona I, Sperlagh B, Magloczky Z, Santha E, Kofalvi A, Czijak S, Mackie K, Vizi ES, Freund TF: GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus. Neuroscience 2000; 100: 797-804.
10. Kofalvi A, Rodrigues RJ, Ledent C, Mackie K, Vizi ES, Cunha RA, Sperlagh B: Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: A combined immunochemical and pharmacological analysis. J Neurosci 2005; 25: 2874-2884.
11. Gardner EL, Paredes W, Smith D, Donner A, Milling C, Cohen D, Morrison D: Facilitation of brain stimulation reward byδ 9 -tetrahydrocannabinol. Psychopharmacology 1988; 96: 142-144.
12. Sakurai-Yamashita Y, Kataoka Y, Fujiwara M, Mine K, Ueki S:δ 9 tetrahydrocannabinol facilitates striatal dopaminergic transmission. Pharmacol Biochem Behav 1989; 33: 397-400.
13. French ED, Dillon K, Wu X: Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport 1997; 8: 649-652.
14. Gessa GL, Melis M, Muntoni AL, Diana M: Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors. Eur J Pharmacol 1998; 341: 39-44.
15. Tanda G, Pontieri FE, Di Chiara G: Cannabinoid and heroin activation of mesolimbic dopamine transmission by a commonμ 1 opioid receptor mechanism. Science 1997; 276: 2048-2050.
16. Van Der Stelt M, Di Marzo V: The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: Implications for neurological and psychiatric disorders. Eur J Pharmacol 2003; 480: 133-150.
17. Wachtel SR, El Sohly MA, Ross SA, Ambre J, de Wit H: Comparison of the subjective effects ofδ9 -tetrahydrocannabinol and marijuana in humans. Psychopharmacology 2002; 161: 331-339.
18. Semple DM, McIntosh AM, Lawrie SM: Cannabis as a risk factor for psychosis: Systematic review. J Psychopharmacol 2005; 19: 187-194.
19. Cohen M, Solowij N, Carr V: Cannabis, cannabinoids and schizophrenia: Integration of the evidence. Aust NZ J Psychiatry 2008; 42: 357-368.
20. Hall WD, Degenhardt L: Cannabis use and the risk of developing a psychotic disorder. World Psychiatry 2008; 7: 68-71.
21. Childers SR, Breivogel CS: Cannabis and endogenous cannabinoid systems. Drug Alcohol Depend 1998; 51: 173-187.
22. DeVane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC: Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988; 34: 605-613.
23. Compton DR, Gold LH, Ward SJ, Balster RL, Martin BR: Aminoalkylindole analogs: Cannabimimetic activity of a class of compounds structurally distinct fromδ 9 -tetrahydrocannabinol. J Pharmacol Exp Ther 1992; 263: 1118-1126.
24. Ottani A, Giuliani D: HU 210: A potent tool for investigations of the cannabinoid system. CNS Drug Rev 2001; 7: 131-145.
25. Dalton VS, Wang H, Zavitsanou K: HU210- induced downregulation in cannabinoid CB1 receptor binding strongly correlates with body weight loss in the adult rat. Neurochem Res 2009; 34: 1343-1353.
26. Dalton VS, Zavitsanou K: Differential treatment regimen-related effects of cannabinoids on D1 and D2 receptors in adolescent and adult rat brain. J Chem Neuroanat 2010; 40: 272-280.
27. Sim LJ, Selley DE, Childers SR: In vitro autoradiography of receptor-activated G-proteins in rat brain by agonist-stimulated guanylyl 5′ -[γ -[ 35 S]thio]-triphosphate binding. Proc Natl Acad Sci USA 1995; 92: 7242-7246.
28. Happe HK, Bylund DB, Murrin C: Agoniststimulated [ 35 S]GTPγ S autoradiography: Optimization for high sensitivity. Eur J Pharmacol 2001; 422: 1-13.
29. Breivogel CS: Cannabinoid receptor binding to membrane homogenates and cannabinoid- stimulated [ 35 S]GTPγ S binding to membrane homogenates or intact cultured cells; in Onaivi ES (ed): Marijuana and Cannabinoid Research. Totowa, Humana Press, 2006, pp 149-162.
30. Paxinos G, Watson C: The Rat Brain in Stereotaxic Coordinates. Sydney, Academic Press, 2007.
31. Sim-Selley LJ: Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit Rev Neurobiol 2003; 15: 91-119.
32. Kenalin T: Efficacy; in Kenalin T (ed): Pharmacologic Analysis of Drug-Receptor Interaction. New York, Raven Press, 1993, pp 249- 277.
33. Sim LJ, Hampson RE, Deadwyler SA, Childers SR: Effects of chronic treatment withδ 9 -tetrahydrocannabinol on cannabinoid- stimulated [ 35 S]GTPγ S autoradiography in rat brain. J Neurosci 1996; 16: 8057-8066.
34. Asano T, Pedersen SE, Scott CW, Ross EM: Reconstitution of catecholamine-stimulated binding of guanosine-5′ -O-(3-thiotriphosphate) to the stimulatory GTP-binding protein of adenylate cyclase. Biochemistry 1984; 23: 5460-5467.
35. Florio VA, Sternweis PC: Mechanisms of muscarinic receptor action on G o in reconstituted phospholipid vesicles. J Biol Chem 1989; 264: 3909-3915.
36. Traynor JF, Nahorski SR: Modulation by mopioid agonists of guanosine-5′ -O-(3-[ 35 S] thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol Pharmacol 1995; 47: 848-854.
37. Lorenzen A, Fuss M, Vogt H, Schwabe U: Measurement of guanine nucleotide-binding protein activation by A 1 adenosine receptor agonists in bovine brain membranes: Stimulation of guanosine-5′ -O-(3-[ 35 S]thio) triphosphate binding. Mol Pharmacol 1993; 4: 115-123.
38. Oviedo A, Glowa J, Herkenham M: Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: A quantitative autoradiographic study. Brain Res 1993; 616: 293-302.
39. De Fonseca FR, Gorriti MA, Fernandez-Ruiz JJ, Palomo T, Ramos JA: Downregulation of rat brain cannabinoid binding sites after chronicδ9 -tetrahydrocannabinol treatment. Pharmacol Biochem Behav 1994; 47: 33-40.
40. Westlake TM, Howlett AC, Ali SF, Paule MG, Scallet AC, Slikker W: Chronic exposure toδ9 -tetrahydrocannabinol fails to irreversibly alter brain cannabinoid receptors. Brain Res 1991; 544: 145-149.
41. Abood ME, Sauss C, Fan F, Tilton CL, Martin BR: Development of behavioral tolerance toδ9 -THC without alteration of cannabinoid receptor binding or mRNA levels in whole brain. Pharmacol Biochem Behav 1993; 46: 575-579.
42. Fuxe K, Marcellino D, Rivera A, Diaz-Cabiale Z, Filip M, Gago B, Roberts DCS, Langel U, Genedani S, Ferraro L, de la Calle A, Narvaez J, Tanganelli S, Woods A, Agnati LF: Receptor-receptor interactions within receptor mosaics. Impact on neuropsychopharmacology. Brain Res Rev 2008; 58: 415-452.
43. O'Neill C, Evers-Donnelly A, Nicholson D, O'Boyle KM, O'Connor JJ: D2 receptor-mediated inhibition of dopamine release in the rat striatum in vitro is modulated by CB1 receptors: Studies using fast cyclic voltammetry. J Neurochem 2009; 108: 545-551.
44. Romero J, Lastres-Becker I, de Miguel R, Berrendero F, Ramos JA, Fernández-Ruiz J: The endogenous cannabinoid system and the basal ganglia: Biochemical, pharmacological, and therapeutic aspects. Pharmacol Ther 2002; 95: 137-152.
45. Romero J, de Miguel R, Garcia-Palomero E, Fernández-Ruiz JJ, Ramos JA: Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function. Brain Res 1995; 694: 223-232.
46. Romero J, Garcia L, Cebeira M, Zadrozny D, Fernández-Ruiz JJ, Ramos JA: The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behaviour: Role of nigrostriatal dopaminergic neurons. Life Sci 1995; 6: 2033-2040.
47. Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Vogt LJ, Sim-Selley LJ: Chronicδ 9 -tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain. J Neurochem 1999; 73: 2447-2459.
48. Navarro M, Fernandez-Ruiz JJ, de Miguel R, Hernandez ML, Cebeira M, Ramos JA: Motor disturbances induced by an acute dose ofδ 9 - Tetrahydrocannabinol: Possible involvement of nigrostriatal dopaminergic alterations. Pharmacol Biochem Behav 1993; 45: 292-298.
49. Pertwee RG, Greentree SG:δ 9 -tetrahydrocannabinol- induced catalepsy in mice is enhanced by pretreatment with flurazepam or chlordiazepoxide. Neuropharmacology 1988; 27: 485-491.
50. Maneuf YP, Nash JE, Crossman AR, Brotchie JM: Activation of the cannabinoid receptor byδ 9 -tetrahydrocannabinoid reducesγ - Aminobutyric acid uptake in the globus pallidus. Eur J Pharmacol 1996; 308: 161-164.
51. Chen J, Paredes W, Li J, Smith D, Lowinson J, Gardner EL: Delta-9-tetrahydrocannabinol produces naloxone-blackade enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freelymoving rats as measured by intracerebral microdialysis. Psychopharmacology 1990; 102: 156-162.
52. Gardner EL, Vorel RH: Cannabinoid transmission and reward-related events. Neurobiol Dis 1998; 5: 502-533.
53. de Lago E, de Miguel R, Lastres-Becker I, Ramos JA, Fernandez-Ruiz J: Involvement of Vanilloid-like receptors in the effects of anandamide on motor behaviour and nigrostriatal dopaminergic activity: In vivo and in vitro evidence. Brain Res 2004; 1007: 152-159.
54. Glass M, Felder CC: Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: Evidence for a G s linkage to the CB1 receptor. J Neurosci 1997; 17: 5327-5333.
55. Sulcova E, Mechoulam R, Fride E: Biphasic effects of anandamide. Pharmacol Biochem Behav 1998; 59: 347-352.
56. Sañudo-Peña MC, Romero J, Seale GE, Fernandez- Ruiz JJ, Walker JM: Activational role of cannabinoids on movement. Eur J Pharmacol 2000; 391: 269-274.
57. Pistis MM, Perra S, Pillolla G, Melis M, Gessa GL, Muntoni AL: Cannabinoids modulate neuronal firing in the rat basolateral amygdala: Evidence for CB1- and non-CB2-mediated actions. Neuropharmacology 2004; 46: 115-125.
58. Hill MN, Froese LM, Morrish AC, Sun JC, Floresco SB: Alterations in behavioural flexibility by cannabinoid CB1 receptor agonists and antagonists. Psychopharmacology 2006; 187: 245-259.
59. Tzavara ET, Wade M, Nomikos GG: Biphasic effects of cannabinoids on acetylcholine release in the hippocampus site and mechanism of action. J Neurosci 2003; 23: 9374-9384.
60. Margulies JE, Hammer RP:δ 9 -Tetrahydrocannabinol alter cerebral metabolism in a biphasic, dose-dependent manner in rat brain. Eur J Pharmacol 1991; 202: 373-378.
61. Marsicano G, Lutz B: Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci 1999; 11: 4213-4225.
62. Ferraro L, Tomasini MC, Cassano T, Bebe BW, Siniscalchi A, O'Connor WT, Magee P, Tanganelli S, Cuomo V, Antonelli T: Cannabinoid receptor agonist WIN 55,212-2 inhibits rat cortical dialysate gamma-aminobutyric acid levels. J Neurosci Res 2001; 66: 298-302.
63. Breivogel CS, Sim LJ, Childers SR: Regional differences in cannabinoid receptor/G-protein coupling in rat brain. J Pharmacol Exp Ther 1997; 282: 1632-1642.
64. Wager-Miller J, Westenbroek R, Mackie K: Dimerization of G protein-coupled receptors: CB1 cannabinoid receptors as an example. Chem Phys Lipids 2002; 121: 83-89.
65. Romero J, Berrendero F, Gracia-Gil L, Lin SY, Makriannis A, Ramos JA, Fernandez- Ruiz JJ: Cannabinoid receptor and WIN55,212-2-stimulated [ 35 S]GTPγ S binding and cannabinoid receptor mRNA levels in several brain structures of adult male rats chronically exposed to R- methanandamide. Neurochem Int 1999; 34: 473-482.